237 related articles for article (PubMed ID: 37511550)
1. Epithelial-to-Mesenchymal Transition Gene Signature in Circulating Melanoma Cells: Biological and Clinical Relevance.
Rapanotti MC; Cugini E; Campione E; Di Raimondo C; Costanza G; Rossi P; Ferlosio A; Bernardini S; Orlandi A; De Luca A; Bianchi L
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511550
[TBL] [Abstract][Full Text] [Related]
2. Minimal Residual Disease in Melanoma:molecular characterization of in transit cutaneous metastases and Circulating Melanoma Cells recognizes an expression panel potentially related to disease progression.
Rapanotti MC; Viguria TMS; Spallone G; Terrinoni A; Rossi P; Costanza G; Campione E; Lombardo P; Pathirannehalage CD; Orlandi A; Bernardini S; Bianchi L
Cancer Treat Res Commun; 2020; 25():100262. PubMed ID: 33338742
[TBL] [Abstract][Full Text] [Related]
3. Stem-Mesenchymal Signature Cell Genes Detected in Heterogeneous Circulating Melanoma Cells Correlate With Disease Stage in Melanoma Patients.
Rapanotti MC; Campione E; Suarez Viguria TM; Spallone G; Costanza G; Rossi P; Orlandi A; Valenti P; Bernardini S; Bianchi L
Front Mol Biosci; 2020; 7():92. PubMed ID: 32548126
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.
Blassl C; Kuhlmann JD; Webers A; Wimberger P; Fehm T; Neubauer H
Mol Oncol; 2016 Aug; 10(7):1030-42. PubMed ID: 27157930
[TBL] [Abstract][Full Text] [Related]
5. Circulating melanoma cells in the diagnosis and monitoring of melanoma: an appraisal of clinical potential.
Mumford BS; Robertson GP
Mol Diagn Ther; 2014 Apr; 18(2):175-83. PubMed ID: 24297151
[TBL] [Abstract][Full Text] [Related]
6. Monosomy 3 Influences Epithelial-Mesenchymal Transition Gene Expression in Uveal Melanoma Patients; Consequences for Liquid Biopsy.
Soltysova A; Sedlackova T; Dvorska D; Jasek K; Chokhachi Baradaran P; Horvathova Kajabova V; Demkova L; Buocikova V; Kurucova T; Lyskova D; Furdova A; Minarik G; Babal P; Dankova Z; Smolkova B
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348918
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells.
Fomeshi MR; Ebrahimi M; Mowla SJ; Khosravani P; Firouzi J; Khayatzadeh H
Cell Mol Biol Lett; 2015 Sep; 20(3):448-65. PubMed ID: 26208390
[TBL] [Abstract][Full Text] [Related]
8. Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanoma.
Joshi P; Jacobs B; Derakhshan A; Moore LR; Elson P; Triozzi PL; Borden E; Zborowski M
Oncotarget; 2014 May; 5(9):2450-61. PubMed ID: 24811334
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer.
Mego M; Karaba M; Minarik G; Benca J; Silvia J; Sedlackova T; Manasova D; Kalavska K; Pindak D; Cristofanilli M; Reuben JM; Mardiak J
Anticancer Res; 2019 Apr; 39(4):1829-1837. PubMed ID: 30952723
[TBL] [Abstract][Full Text] [Related]
10. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
[TBL] [Abstract][Full Text] [Related]
11. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.
Fenouille N; Tichet M; Dufies M; Pottier A; Mogha A; Soo JK; Rocchi S; Mallavialle A; Galibert MD; Khammari A; Lacour JP; Ballotti R; Deckert M; Tartare-Deckert S
PLoS One; 2012; 7(7):e40378. PubMed ID: 22911700
[TBL] [Abstract][Full Text] [Related]
12. Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients.
Ruiz C; Li J; Luttgen MS; Kolatkar A; Kendall JT; Flores E; Topp Z; Samlowski WE; McClay E; Bethel K; Ferrone S; Hicks J; Kuhn P
Phys Biol; 2015 Jan; 12(1):016008. PubMed ID: 25574741
[TBL] [Abstract][Full Text] [Related]
13. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
[TBL] [Abstract][Full Text] [Related]
14. Circulating melanoma cells and survival in metastatic melanoma.
Rao C; Bui T; Connelly M; Doyle G; Karydis I; Middleton MR; Clack G; Malone M; Coumans FA; Terstappen LW
Int J Oncol; 2011 Mar; 38(3):755-60. PubMed ID: 21206975
[TBL] [Abstract][Full Text] [Related]
15. Detection of circulating melanoma cells in the blood of melanoma patients: a preliminary study.
Roland CL; Ross MI; Hall CS; Laubacher B; Upshaw J; Anderson AE; Lucci A
Melanoma Res; 2015 Aug; 25(4):335-41. PubMed ID: 26011119
[TBL] [Abstract][Full Text] [Related]
16. Stability of the hybrid epithelial/mesenchymal phenotype.
Jolly MK; Tripathi SC; Jia D; Mooney SM; Celiktas M; Hanash SM; Mani SA; Pienta KJ; Ben-Jacob E; Levine H
Oncotarget; 2016 May; 7(19):27067-84. PubMed ID: 27008704
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
[TBL] [Abstract][Full Text] [Related]
18. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
Giordano A; Gao H; Anfossi S; Cohen E; Mego M; Lee BN; Tin S; De Laurentiis M; Parker CA; Alvarez RH; Valero V; Ueno NT; De Placido S; Mani SA; Esteva FJ; Cristofanilli M; Reuben JM
Mol Cancer Ther; 2012 Nov; 11(11):2526-34. PubMed ID: 22973057
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells.
Freeman JB; Gray ES; Millward M; Pearce R; Ziman M
J Transl Med; 2012 Sep; 10():192. PubMed ID: 22978632
[TBL] [Abstract][Full Text] [Related]
20. Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
Lee J; Kim H; Lee JE; Shin SJ; Oh S; Kwon G; Kim H; Choi YY; White MA; Paik S; Cheong JH; Kim HS
Gastroenterology; 2018 Sep; 155(3):799-814.e13. PubMed ID: 29775598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
